person · Reporting owner

RHOADS ANN D

Disclosed activity across 8 companies

Tapewire entity: 34772
SEC CIK: 0001250252

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Evoke Pharma IncEVOK · Entity 71094	Director	May 05, 2021	July 23, 2021
GLOBUS MEDICAL INCGMED · Entity 3496	Director	June 04, 2026	June 08, 2026
IRIDEX CORPIRIX · Entity 7882	Director	June 13, 2018	June 16, 2018
QuidelOrtho CorpQDEL · Entity 4986	Director	June 25, 2026	June 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Evoke Pharma Inc

Report date May 05, 2021 · Filed July 23, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2031-05-04	Direct	61,750	Reported balance After 2021-05-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-05-05 · Grant · Acquired 61,750 · Balance 61,750 F1: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date.

GLOBUS MEDICAL INC

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	40,384	Reported balance After 2026-06-04 transaction · row 1 1 source row Row 1 · 2026-06-04 · Exercise / conversion · Acquired 25,000 · Balance 40,384
Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2027-01-30	Direct	0	Reported balance After 2026-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-04 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: These options were granted on January 30, 2017 and are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted on January 30, 2017 and are fully vested.

IRIDEX CORP

Report date June 13, 2018 · Filed June 16, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,690	Reported balance After 2018-06-13 transaction · row 1 1 source row Row 1 · 2018-06-13 · Grant · Acquired 5,690 · Balance 5,690 F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of June 13, 2019 or the date of the Issuer's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of June 13, 2019 or the date of the Issuer's next annual meeting of stockholders.

QuidelOrtho Corp

Report date June 25, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security	Direct	15,532	Reported balance After 2026-06-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027.
Restricted Stock Units (Converted)SEC Table II · derivative / convertible security	Direct	3,698	Reported balance After 2026-06-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-25 · Grant · Acquired 3,698 · Balance 3,698 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4: 924 shares vested on June 25, 2026, 924 shares will vest on September 25, 2026, 925 shares will vest on December 25, 2026, and 925 shares will vest on March 25, 2027.
Restricted Stock Units (Premium)SEC Table II · derivative / convertible security	Direct	369	Reported balance After 2026-06-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-25 · Grant · Acquired 369 · Balance 369 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

F2: The restricted stock units will vest on June 25, 2027.

F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.

F4: 924 shares vested on June 25, 2026, 924 shares will vest on September 25, 2026, 925 shares will vest on December 25, 2026, and 925 shares will vest on March 25, 2027.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Forty Seven, Inc.

Report date April 07, 2020 · Filed April 07, 2020

Section 16 reporting ended · disclosed 2020-04-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-04-07 transaction · row 1 1 source row Row 1 · 2020-04-07 · Disposition to issuer · Disposed 37,414 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-11	Direct	Reported balance After 2020-04-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-04-07 · Disposition to issuer · Disposed 120,147 · Balance 0 F2: This option, which provided for vesting over a four-year period as follows: (i) 26,710 shares subject to the option vested on March 29, 2019, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,412,851.15, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-26	Direct	Reported balance After 2020-04-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-04-07 · Disposition to issuer · Disposed 74,838 · Balance 0 F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,491,635.22, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.75 · Expires 2029-12-12	Direct	Reported balance After 2020-04-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-04-07 · Disposition to issuer · Disposed 107,827 · Balance 0 F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,442,663.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F2: This option, which provided for vesting over a four-year period as follows: (i) 26,710 shares subject to the option vested on March 29, 2019, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,412,851.15, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,491,635.22, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,442,663.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

QUIDEL CORP /DE/

Report date May 27, 2022 · Filed June 01, 2022

Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-27 transaction · row 1 1 source row Row 1 · 2022-05-27 · Disposition to issuer · Disposed 2,248 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-05-27 · Disposition to issuer · Disposed 427 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-05-27 · Disposition to issuer · Disposed 128 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.

F2: Each restricted stock unit represents the right to receive one share of Quidel common stock.

F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).

F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Repare Therapeutics Inc.

Report date January 28, 2026 · Filed January 29, 2026

Section 16 reporting ended · disclosed 2026-01-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2026-01-28 transaction · row 1 1 source row Row 1 · 2026-01-28 · Disposition to issuer · Disposed 4,000 · Balance 0 F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share. F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share.

F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

iTeos Therapeutics, Inc.

Report date August 29, 2025 · Filed August 29, 2025

Section 16 reporting ended · disclosed 2025-08-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.16	Direct	0	Reported balance After 2025-08-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-08-29 · Disposition to issuer · Disposed 27,178 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") F2: (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option")

F2: (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 22, 2024 Filed May 23, 2024 22:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Converted) · Derivative	1,173	$0.00	$0.00	Disclosure SEC source: 0000950170-24-064144 · ownership.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,173 Underlying: Common Stock · 1,173 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 293 shares vested on May 22, 2024, 293 shares will vest on August 22, 2024, 293 shares will vest on November 22, 2024 and 294 shares will vest on February 22, 2025. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 293 shares vested on May 22, 2024, 293 shares will vest on August 22, 2024, 293 shares will vest on November 22, 2024 and 294 shares will vest on February 22, 2025. Read SEC document
May 22, 2024 Filed May 23, 2024 22:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	4,929	$0.00	$0.00	Disclosure SEC source: 0000950170-24-064144 · ownership.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,929 Underlying: Common Stock · 4,929 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 22, 2025. F2 · derivative.expiration_date: The restricted stock units vest on May 22, 2025. Read SEC document
January 26, 2024 Filed Jan 30, 2024 21:50 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $53.75	$0.00	Disclosure SEC source: 0000950170-24-008918 · ownership.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2034-01-26 F1 · derivative.exercise_date: These options were granted on January 26, 2024, and will vest on January 1, 2025. Read SEC document
June 13, 2023 Filed Jun 15, 2023 19:56 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	22,383	$0.00 Strike: $14.77	$0.00	Disclosure SEC source: 0001209191-23-037594 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,383 Underlying: Common Stock · 22,383 shares Expires 2033-06-13 Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:30 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	GrantStock Option (right to buy) · Derivative	27,200	$0.00 Strike: $11.66	$0.00	Disclosure SEC source: 0001209191-23-036332 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document
June 06, 2023 Filed Jun 8, 2023 20:23 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	2,248	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035394 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on June 6, 2023. F3 · derivative.expiration_date: The restricted stock units vested on June 6, 2023. Read SEC document
June 06, 2023 Filed Jun 8, 2023 20:23 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	2,248	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035394 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,496 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 24, 2023 Filed May 26, 2023 00:20 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Premium) · Derivative	109	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032329 · doc4.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109 Underlying: Common Stock · 109 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 24, 2024. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 24, 2024. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document
May 24, 2023 Filed May 26, 2023 00:20 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Converted) · Derivative	546	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032329 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 546 Underlying: Common Stock · 546 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 24, 2023. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 24, 2023. Read SEC document
May 24, 2023 Filed May 26, 2023 00:20 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	2,416	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032329 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,416 Underlying: Common Stock · 2,416 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 24, 2024. F2 · derivative.expiration_date: The restricted stock units vest on May 24, 2024. Read SEC document
January 27, 2023 Filed Jan 30, 2023 21:37 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative	7,500	$0.00 Strike: $12.59	$0.00	Disclosure SEC source: 0001209191-23-005487 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 7,500 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options were granted on January 30, 2013 and are fully vested. Read SEC document
January 27, 2023 Filed Jan 30, 2023 21:37 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionClass A Common Stock	7,500	$12.59	$94,425.00	Disclosure SEC source: 0001209191-23-005487 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 26, 2023 Filed Feb 27, 2023 21:58 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $75.18	$0.00	Disclosure SEC source: 0001209191-23-013237 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2033-01-26 F1 · derivative.exercise_date: These options were granted on January 26, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document
June 09, 2022 Filed Jun 10, 2022 19:54 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	17,538	$0.00 Strike: $18.78	$0.00	Disclosure SEC source: 0001209191-22-036140 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,538 Underlying: Common Stock · 17,538 shares Expires 2032-06-09 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
June 06, 2022 Filed Jun 8, 2022 22:19 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Premium) · Derivative	203	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035178 · doc4.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203 Underlying: Common Stock · 203 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on June 6, 2023. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on June 6, 2023. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document
June 06, 2022 Filed Jun 8, 2022 22:19 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Converted) · Derivative	1,017	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035178 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017 Underlying: Common Stock · 1,017 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, June 6, 2022. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, June 6, 2022. Read SEC document
June 06, 2022 Filed Jun 8, 2022 22:19 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	2,248	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035178 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,248 Underlying: Common Stock · 2,248 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on June 6, 2023. F2 · derivative.expiration_date: The restricted stock units vest on June 6, 2023. Read SEC document
May 27, 2022 Filed Jun 1, 2022 16:26 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Disposition to issuerRestricted Stock Units · Derivative	128	$0.00	$0.00	Disclosure SEC source: 0000899243-22-020409 · doc4.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document
May 27, 2022 Filed Jun 1, 2022 16:26 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Disposition to issuerRestricted Stock Units · Derivative	427	$0.00	$0.00	Disclosure SEC source: 0000899243-22-020409 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 427 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document
May 27, 2022 Filed Jun 1, 2022 16:26 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Disposition to issuerCommon Stock	2,248	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-020409 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. Read SEC document
May 27, 2022 Filed Jun 1, 2022 21:39 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units · Derivative	128	$0.00	$0.00	Disclosure SEC source: 0000899243-22-020501 · doc4.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128 Underlying: Common Stock · 128 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F3 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document
May 27, 2022 Filed Jun 1, 2022 21:39 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units · Derivative	427	$0.00	$0.00	Disclosure SEC source: 0000899243-22-020501 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427 Underlying: Common Stock · 427 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F3 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document
May 27, 2022 Filed Jun 1, 2022 21:39 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	2,248	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-020501 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,248 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. Read SEC document
May 18, 2022 Filed May 20, 2022 19:48 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	1,624	$0.00	$0.00	Disclosure SEC source: 0001209191-22-031191 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,624 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. Read SEC document
May 18, 2022 Filed May 20, 2022 19:48 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionCommon Stock	1,624	$0.00	$0.00	Disclosure SEC source: 0001209191-22-031191 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document
May 13, 2022 Filed May 16, 2022 23:29 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	GrantStock Option (right to buy) · Derivative	49,000	$0.00 Strike: $9.55	$0.00	Disclosure SEC source: 0001209191-22-029369 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Shares · 49,000 shares Expires 2032-05-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document
January 27, 2022 Filed Jan 31, 2022 21:58 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $63.68	$0.00	Disclosure SEC source: 0001209191-22-005612 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: These options were granted on January 27, 2022, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2023, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:17 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	16,608	$0.00 Strike: $26.03	$0.00	Disclosure SEC source: 0000899243-21-025130 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,608 Underlying: Common Stock · 16,608 shares Expires 2031-06-17 F1 · derivative.exercise_date: This stock option shall vest and become exercisable in full upon the earlier to occur of (a) June 17, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
May 18, 2021 Filed May 20, 2021 20:38 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Premium) · Derivative	128	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034707 · doc4.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128 Underlying: Common Stock · 128 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 18, 2022. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 18, 2022. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. Read SEC document
May 18, 2021 Filed May 20, 2021 20:38 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Converted) · Derivative	427	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034707 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427 Underlying: Common Stock · 427 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 18, 2021. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 18, 2021. Read SEC document
May 18, 2021 Filed May 20, 2021 20:38 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Equity Grant) · Derivative	1,624	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034707 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624 Underlying: Common Stock · 1,624 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 18, 2022. F2 · derivative.expiration_date: The restricted stock units vest on May 18, 2022. Read SEC document
May 13, 2021 Filed May 14, 2021 20:52 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	GrantStock Option (right to buy) · Derivative	21,000	$0.00 Strike: $32.44	$0.00	Disclosure SEC source: 0001209191-21-032778 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document
May 12, 2021 Filed May 14, 2021 20:10 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionRestricted Stock Units · Derivative	624	$0.00	$0.00	Disclosure SEC source: 0001209191-21-032976 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 624 shares Expires 2021-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
May 12, 2021 Filed May 14, 2021 20:10 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionCommon Stock	624	$0.00	$0.00	Disclosure SEC source: 0001209191-21-032976 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document
May 05, 2021 Filed Jul 23, 2021 18:26 UTC	Evoke Pharma Inc EVOK · Entity 71094	GrantStock Option (Right to Buy) · Derivative	61,750	$0.00 Strike: $1.55	$0.00	Disclosure SEC source: 0001209191-21-048027 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,750 Underlying: Common Stock · 61,750 shares Expires 2031-05-04 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:32 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative	15,384	$0.00 Strike: $10.66	$0.00	Disclosure SEC source: 0001209191-21-016873 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,384 shares Expires 2021-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options were granted on July 28, 2011 and are fully vested. F2 · derivative.underlying: Initially the stock option provided a right to buy the Company's Class C Common Stock. Upon the closing of the Company's initial public offering, all shares of the Company's Class C Common Stock automatically converted into shares of the Company's Class A Common Stock on a one-for-one basis. As a result, this stock option automatically converted into a right to buy the Company's Class A Common Stock. Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:32 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionClass A Common Stock	15,384	$10.66	$163,993.44	Disclosure SEC source: 0001209191-21-016873 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 14, 2021 Filed Jan 19, 2021 22:02 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $65.05	$0.00	Disclosure SEC source: 0001209191-21-004053 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2031-01-14 F1 · derivative.exercise_date: These options were granted on January 14, 2021, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2022, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document
August 24, 2020 Filed Aug 26, 2020 20:27 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units · Derivative	624	$0.00	$0.00	Disclosure SEC source: 0001209191-20-048469 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624 Underlying: Common Stock · 624 shares Expires 2021-05-12 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. Read SEC document
July 23, 2020 Filed Jul 24, 2020 19:19 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	16,608	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0000899243-20-020436 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,608 shares Expires 2030-07-23 F1 · derivative.exercise_date: This stock option shall vest over 3 years, with 1/3 vesting on July 23, 2021 and thereafter in equal monthly installments over the next 24 months subject to the Reporting Person's continued service to the Issuer. Read SEC document
July 23, 2020 Filed Oct 21, 2020 16:55 UTC Amendment	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	16,608	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0000899243-20-028901 · doc4a.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,608 shares Expires 2030-07-23 F1 · derivative.exercise_date: This amendment is being filed solely for the purpose of correcting the vesting schedule, as follows: this stock option shall vest on the earlier of (i) the first anniversary of the grant date or (ii) the Company's next annual meeting of stockholders following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 23, 2020 Filed Jun 25, 2020 21:55 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	PurchaseCommon Shares	4,000	$20.00	$80,000.00	Disclosure SEC source: 0001209191-20-038970 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document
June 18, 2020 Filed Jun 19, 2020 12:06 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	GrantEmployee Stock Option (right to buy) · Derivative	38,907	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001209191-20-037781 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,907 Underlying: Common Stock · 38,907 shares Expires 2030-06-18 F1 · derivative.exercise_date: Thirty-three percent (33%) of the shares subject to the option shall vest on June 18, 2021, and one twenty-forth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document
May 27, 2020 Filed May 29, 2020 16:48 UTC	Evoke Pharma Inc EVOK · Entity 71094	GrantStock Option (Right to Buy) · Derivative	61,750	$0.00 Strike: $2.60	$0.00	Disclosure SEC source: 0001209191-20-032971 · doc4.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,750 Underlying: Common Stock · 61,750 shares Expires 2030-05-26 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document
April 07, 2020 Filed Apr 7, 2020 12:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	Disposition to issuerStock Option (right to buy) · Derivative	107,827	Not disclosed Strike: $35.75	Not disclosed	Disclosure SEC source: 0001209191-20-023713 · doc4.xml · derivative · entry 4 RHOADS ANN D · CIK 0001250252 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,827 shares Expires 2029-12-12 F4 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,442,663.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F4 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,442,663.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document
April 07, 2020 Filed Apr 7, 2020 12:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	Disposition to issuerStock Option (right to buy) · Derivative	74,838	Not disclosed Strike: $8.76	Not disclosed	Disclosure SEC source: 0001209191-20-023713 · doc4.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,838 shares Expires 2028-04-26 F3 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,491,635.22, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F3 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,491,635.22, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document
April 07, 2020 Filed Apr 7, 2020 12:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	Disposition to issuerStock Option (right to buy) · Derivative	120,147	Not disclosed Strike: $8.76	Not disclosed	Disclosure SEC source: 0001209191-20-023713 · doc4.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,147 shares Expires 2028-04-11 F2 · price: This option, which provided for vesting over a four-year period as follows: (i) 26,710 shares subject to the option vested on March 29, 2019, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,412,851.15, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F2 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: (i) 26,710 shares subject to the option vested on March 29, 2019, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,412,851.15, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document
April 07, 2020 Filed Apr 7, 2020 12:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	Disposition to issuerCommon Stock	37,414	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-023713 · doc4.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. Read SEC document
April 01, 2020 Filed Apr 3, 2020 17:51 UTC	Forty Seven, Inc. FTSV · Entity 16035	Exercise / conversionStock Option (right to buy) · Derivative	20,950	$0.00 Strike: $8.76	$0.00	Disclosure SEC source: 0001209191-20-023388 · doc4.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,147 Underlying: Common Stock · 20,950 shares Expires 2028-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 26,710 shares vested on March 29, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments beginning March 29, 2019, subject to Reporting Person's continuous service as of each such date. Read SEC document
April 01, 2020 Filed Apr 3, 2020 17:51 UTC	Forty Seven, Inc. FTSV · Entity 16035	SaleCommon Stock	1,924	$95.43	$183,597.70	Disclosure SEC source: 0001209191-20-023388 · doc4.xml · nonDerivative · entry 2 RHOADS ANN D · CIK 0001250252 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,414 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.